Medical devices company Medigus Ltd. (TASE:MDGS) announced Tuesday the fee schedule for its MUSE treatment in the US, six months after government insurers accepted an American Medical Association recommendation to reimburse esophagus procedures
Medigus, which developed an alternative to surgery for patients suffering from gastroesophageal reflux disease (GERD), said the Centers for Medicare and Medicaid Services (CMS) announced a reimbursement of $445 for every procedure a doctor conducts with its product, the Medigus Ultrasonic Surgical Endostapler (MUSE).
Outpatient hospitals will be reimbursed $3,614 for each procedure; both payment schedules will begin January 2016.
“The new reimbursement values reflect the medical community’s recognition of transoral procedures such as MUSE as valuable clinical options for physicians and patients,” said CEO Chris Rowland. “CMS’ decision could further support the growing availability of MUSE in the US by providing physicians with appropriate reimbursement for procedures completed with MUSE.”
Medigus is valued at NIS 96 million. The company has been trading on the Tel Aviv Stock Exchange, but in the past few months began trading on Wall Street, using American Depositary Receipts.
The share price was boosted on the local exchange after Medigus released the reimbursement report.
Published by Globes [online], Israel business news - www.globes-online.com - on November 3, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015